Subjects were given Filament’s psilocybin drug candidate in the first Canadian trial with the purpose of psychedelic therapist training VANCOUVER, BC, Sept. 1, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical-stage natural psychedelic drug development company, and ATMA Journey Centers (“ATMA”), a company focused on delivering…


Previous articleReunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders
Next articleOptimi Health Provides Progress Report On Year Of Commercialization